17 results on '"Garcia Gil E"'
Search Results
2. Clinical Effectiveness of Benralizumab Is Independent of Baseline FeNO in Severe Eosinophilic Asthma: A Retrospective Real-World Observation Study in Five UK Severe Asthma Centers
3. Integrated Safety and Efficacy Among Patients with Severe Asthma Receiving Benralizumab for Up to Five Years
4. Adrenal Insufficiency Is Not a Barrier to OCS Elimination in the PONENTE Study
5. Eosinophil as a Biomarker of Severity and Clinically Important Asthma Outcomes in Benralizumab Phase III Studies
6. OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study
7. Eosinophil Counts and Fractional Exhaled Nitric Oxide Levels After Cessation of Tezepelumab: Results from the PATHWAY Phase 2b Study
8. Exacerbation Reduction and Early and Sustained Improvements in SGRQ, Lung Function, and Symptoms of Nasal Polyposis with Benralizumab for Severe, Eosinophilic Asthma: Phase IIIb ANDHI Trial
9. Enabling Reductions in Maintenance ICS/LABA Therapy Using as Needed Anti-Inflammatory Reliever for Patients with Severe Eosinophilic Asthma Controlled with Benralizumab: SHAMAL Phase IV Clinical Study
10. Aclidinium Bromide Added to a Long-Acting B2-Agonist +/- Inhaled Corticosteroid: Effects on Exacerbations, Lung Function, and Symptoms in Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Risk Factors (ASCENT-COPD)
11. The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial
12. Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study
13. Aclidinium Bromide Treatment in Patients Receiving Beta-Blockers: Effects on MACE, Moderate/Severe COPD Exacerbations, and Lung Function in Patients with Moderate-to-Very Severe COPD and Cardiovascular Risk Factors (ASCENT-COPD)
14. Oral Corticosteroid Tapering During Benralizumab Treatment of Severe, Uncontrolled Eosinophilic Asthma: PONENTE Phase IIIb Clinical Trial
15. A Phase III Study Evaluating Aclidinium Bromide, a Novel Long-Acting Antimuscarinic, in Patients with COPD: ACCLAIM/COPD I.
16. Efficacy and Safety of the Novel, Long-Acting Antimuscarinic, Aclidinium Bromide, in COPD Patients in a Phase III Study: ACCLAIM/COPD II.
17. Pharmacokinetics and Safety of Aclidinium Bromide, a Novel, Long-Acting Antimuscarinic, in Subjects with Renal Impairment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.